Home > Publications database > Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor. > print

001     181116
005     20240301130850.0
024 7 _ |a 10.18632/oncotarget.21932
|2 doi
024 7 _ |a pmid:29228610
|2 pmid
024 7 _ |a pmc:PMC5722562
|2 pmc
037 _ _ |a DKFZ-2022-01785
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Alimova, Irina
|b 0
245 _ _ |a Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
260 _ _ |a [S.l.]
|c 2017
|b Impact Journals LLC
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660554958_9237
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Atypical teratoid rhabdoid tumor (ATRT) is an aggressive and malignant pediatric brain tumor. Polo-like kinase 1 (PLK1) is highly expressed in many cancers and essential for mitosis. Overexpression of PLK1 promotes chromosome instability and aneuploidy by overriding the G2-M DNA damage and spindle checkpoints. Recent studies suggest that targeting PLK1 by small molecule inhibitors is a promising approach to tumor therapy. We investigated the effect of PLK1 inhibition in ATRT. Gene expression analysis showed that PLK1 was overexpressed in ATRT patient samples and tumor cell lines. Genetic inhibition of PLK1 with shRNA potently suppressed ATRT cell growth in vitro. Treatment with the PLK1 inhibitor BI 6727 (Volasertib) significantly decreased cell growth, inhibited clonogenic potential, and induced apoptosis. BI6727 treatment led to G2-M phase arrest, consistent with PLK1's role as a critical regulator of mitosis. Moreover, inhibition of PLK1 by BI6727 suppressed the tumor-sphere formation of ATRT cells. Treatment also significantly decreased levels of the DNA damage proteins Ku80 and RAD51 and increased γ-H2AX expression, indicating that BI 6727 can induce DNA damage. Importantly, BI6727 significantly enhanced radiation sensitivity of ATRT cells. In vivo, BI6727 slowed growth of ATRT tumors and prolonged survival in a xenograft model. PLK1 inhibition is a compelling new therapeutic approach for treating ATRT, and the use of BI6727 should be evaluated in clinical studies.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a ATRT
|2 Other
650 _ 7 |a Polo-like kinase 1
|2 Other
650 _ 7 |a SMARCB1
|2 Other
650 _ 7 |a volasertib
|2 Other
700 1 _ |a Pierce, Angela M
|b 1
700 1 _ |a Harris, Peter
|b 2
700 1 _ |a Donson, Andrew
|b 3
700 1 _ |a Birks, Diane K
|b 4
700 1 _ |a Prince, Eric
|b 5
700 1 _ |a Balakrishnan, Ilango
|b 6
700 1 _ |a Foreman, Nicholas K
|b 7
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 8
|u dkfz
700 1 _ |a Hoffman, Lindsey
|b 9
700 1 _ |a Venkataraman, Sujatha
|b 10
700 1 _ |a Vibhakar, Rajeev
|b 11
773 _ _ |a 10.18632/oncotarget.21932
|g Vol. 8, no. 57, p. 97290 - 97303
|0 PERI:(DE-600)2560162-3
|n 57
|p 97290 - 97303
|t OncoTarget
|v 8
|y 2017
|x 1949-2553
909 C O |o oai:inrepo02.dkfz.de:181116
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2020-09-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2020-09-03
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2020-09-03
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21